特讯热点！意大利歌剧与芭蕾经典即将在大银幕绽放：北京卢米埃影城2023年意大利影像展即将开幕

意大利歌剧与芭蕾经典即将在大银幕绽放：北京卢米埃影城2023年意大利影像展即将开幕

北京 - 2023年4月7日，由卢米埃影城主办的“2023年意大利影像展”将在北京芳草地影城和长楹天街IMAX影城盛大开幕，为观众带来一场美轮美奂的意大利歌剧与芭蕾艺术盛宴。

本次影展精选了来自意大利顶尖歌剧院和芭蕾舞团的十部经典作品，包括歌剧《灰姑娘》、《塞维利亚理发师》、《茶花女》以及芭蕾舞剧《罗密欧与朱丽叶》、《海盗》、《睡美人》、《舞姬》和《吉赛尔》。这些作品不仅代表了意大利歌剧与芭蕾艺术的最高水平，也蕴含着丰富的人文内涵和深刻的艺术哲理。

观众将在大银幕上欣赏到

• 罗马歌剧院罗西尼歌剧《灰姑娘》中大胆前卫的奇装异服和蒂芙尼蓝的时尚布景所营造的“超现实”童话氛围；
• 罗马歌剧院罗西尼歌剧《塞维利亚理发师》中打破舞台边界的创新舞台设计；
• 罗马歌剧院威尔第歌剧《茶花女》中唯美浪漫的爱情故事和感人肺腑的表演；
• 斯卡拉歌剧院芭蕾舞团《罗密欧与朱丽叶》中永恒的爱情故事和深刻的戏剧性；
• 斯卡拉歌剧院芭蕾舞团《海盗》中充满异域风情的冒险故事和芭蕾炫技名场面；
• 斯卡拉歌剧院芭蕾舞团《睡美人》中梦幻奢华的舞台效果和纯正的古典芭蕾编舞；
• 斯卡拉歌剧院芭蕾舞团《舞姬》中高度复杂的舞蹈语汇和人性化的角色刻画；
• 罗马歌剧院芭蕾舞团《吉赛尔》中凄美动人的爱情故事和浪漫主义的艺术风格。

卢米埃影城负责人表示：“我们很高兴能够将意大利歌剧与芭蕾艺术的经典作品带到大银幕上，让中国观众有机会领略这些艺术瑰宝的魅力。希望这次影展能够为观众带来难忘的观影体验，并促进中意两国文化交流。”

**“2023年意大利影像展”**不仅是一次文化盛宴，也是一次艺术普及活动。主办方将邀请意大利歌剧与芭蕾专家为观众进行导赏，并举办相关讲座和研讨会，帮助观众更好地了解和欣赏意大利歌剧与芭蕾艺术。

相信此次影展一定会受到广大观众的热烈欢迎，为北京的文化生活增添新的光彩。

附：

• 展映时间：2023年4月7日-16日
• 展映地点：北京卢米埃影城芳草地影城、长楹天街IMAX影城
• 购票渠道：卢米埃影城APP、猫眼、淘票票等

新闻亮点：

• 本次影展是意大利歌剧与芭蕾艺术在中国的首次大规模展映。
• 展映作品阵容强大，汇集了来自意大利顶尖歌剧院和芭蕾舞团的十部经典作品。
• 主办方将邀请意大利歌剧与芭蕾专家为观众进行导赏，并举办相关讲座和研讨会。

此新闻稿件已于2023年3月31日发表在新浪娱乐等媒体平台上。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.